Immunocore Holdings plc reported significant financial results for the second quarter of 2026, with total revenue reaching $115.9 million, an 18.3% increase from $98.0 million in the same period last year. For the first half of 2026, the company generated $222.6 million in revenue, up 16.0% from $191.8 million in the first half of 2025. The growth in revenue is primarily attributed to increased sales of KIMMTRAK, its lead product, particularly in the United States, where sales rose to $74.9 million from $64.1 million year-over-year. The company also reported a net loss of $808,000 for the second quarter, a significant improvement compared to a loss of $10.3 million in the same quarter of 2025.
In terms of operational metrics, Immunocore's cash and cash equivalents increased to $484.9 million as of June 30, 2026, compared to $467.7 million at the end of 2025. The company’s total assets rose to $1.12 billion, up from $1.07 billion at the end of the previous fiscal year. Accounts receivable also saw a notable increase, climbing to $95.4 million from $74.0 million, reflecting the growing sales volume. The company’s total liabilities increased slightly to $699.6 million, up from $686.2 million, while shareholders' equity improved to $419.8 million from $381.0 million.
Strategically, Immunocore has continued to expand its clinical pipeline and product offerings. The company is actively enrolling patients in the Phase 3 TEBE-AM trial for tebentafusp, which is being evaluated as a treatment for advanced cutaneous melanoma. Additionally, the company presented promising data at the 2026 American Society of Clinical Oncology Meeting regarding its PRAME-targeted ImmTAC brenetafusp, indicating improved clinical activity in advanced melanoma patients. The company has also launched KIMMTRAK in over 30 countries and received approvals in 39 countries, enhancing its market presence.
Looking ahead, Immunocore anticipates continued investment in research and development, with R&D expenses for the second quarter totaling $73.9 million, up from $69.0 million in the same quarter of 2025. The company expects to incur significant operating losses as it advances its clinical programs and seeks regulatory approvals for additional product candidates. Despite the recent net income reported for the first half of 2026, Immunocore's management indicated that ongoing expenses and the need for further funding remain critical considerations for the company's future operations. The company plans to explore various financing options to support its growth strategy, including potential equity offerings and collaborations.
About Immunocore Holdings plc
Immunocore Holdings plc is a biotechnology company developing immunomodulating medicines using its proprietary ImmTAX platform. Its focus includes cancer, infectious diseases, and autoimmune conditions, with key products like KIMMTRAK for uveal melanoma. The company leverages engineered TCRs to create off-the-shelf bispecific therapeutics targeting intracellular and cell surface proteins, aiming to improve patient outcomes through innovative, targeted immunotherapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov